Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?

Leukemia Research

Volumn 33, Issue 11, 2009, Pages 1459-1462

  Song, Moo Kon ^a   Chung, Joo Seop ^a   Seol, Young Mi ^a   Kim, Seong Geun ^a   Shin, Ho Jin ^a   Choi, Young Jin ^a   Cho, Goon Jae ^a  

^a Pusan National University School of Medicine   (South Korea)

Author keywords

Chronic myelogenous leukemia; Cytogenetic response; Imatinib; Mean cell volume; Sokal score

Indexed keywords

IMATINIB; INTERFERON; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BURST FORMING UNIT E; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE MARKER; DOSE RESPONSE; DRUG DOSE REDUCTION; ERYTHROCYTE VOLUME; FEMALE; HUMAN; MACROCYTIC ANEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ERYTHROCYTE INDICES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68649119755     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.04.017     Document Type: Article

References (16)

1. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., and Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med 341 (1999) 164-172
2. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med 348 (2003) 994-1004
3. Larson R.A., Druker B.J., Guilhot F., O'Brien S.G., Riviere G.J., Krahnke T., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111 (2008) 4022-4028
4. White D.L., Saunders V.A., Dang P., Engler J., Venables A., Zrim S., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110 (2007) 4064-4072
5. Agis H., Sperr W.R., Herndlhofer S., Semper H., Pirc-Danoewinata H., Haas O.A., et al. Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). Ann Oncol 18 (2007) 1834-1841
6. Mauro M.J., and Deininger M.W. Chronic myeloid leukemia in 2006: a perspective. Haematologica 91 (2006) 152-158
7. Goldman J.M. How I treat chronic myeloid leukemia in the imatinib era. Blood 110 (2007) 2828-2837
8. Cortes J., O'Brien S., Quintas A., Giles F., Shan J., Rios M.B., et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 100 (2004) 2396-2402
9. Bartolovic K., Balabanov S., Hartmann U., Komor M., Boehmler A.M., Bühring H.J., et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103 (2004) 523-529
10. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med 355 (2006) 2408-2417
11. Rosti G., Martinelli G., Bassi S., Amabile M., Trabacchi E., Giannini S., et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 103 (2004) 2284-2290
12. Kantarjian H.M., Talpaz M., O'Brien S., Giles F., Garcia-Manero G., Faderl S., et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101 (2003) 473-475
13. Kantarjian H.M., Larson R.A., Guilhot F., O'Brien S.G., Mone M., Rudoltz M., et al. International Randomized Study of Interferon and STI571 (IRIS) Investigators. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115 (2009) 551-560
14. Jabbour E., Kantarjian H.M., Jones D., Shan J., O'Brien S., Reddy N., et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113 (2009) 2154-2160
15. Hochhaus A., Kantarjian H.M., Baccarani M., Lipton J.H., Apperley J.F., Druker B.J., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109 (2007) 2303-2309
16. Kantarjian H.M., Giles F., Gattermann N., Bhalla K., Alimena G., Palandri F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 (2007) 3540-3546